Cerevel Therapeutics Hldg Inc (CERE)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
44.96 +0.33 (+0.74%) 07/31/24 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 44.96 unch (unch) -
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -432,842 | -351,511 | -225,334 | -152,142 | -128,389 |
| Depreciation Amortization | -14,073 | -1,646 | 2,753 | 397 | 177 |
| Accounts payable and accrued liabilities | 2,038 | -763 | 7,278 | 1,417 | 607 |
| Other Working Capital | 16,113 | 28,064 | 15,541 | 17,707 | 343 |
| Other Operating Activity | 86,463 | 32,669 | 21,216 | 14,819 | 56,542 |
| Operating Cash Flow | $-342,301 | $-293,187 | $-178,546 | $-117,802 | $-70,720 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 77,530 | -384,880 | -425,158 | N/A | N/A |
| PPE Investments | -3,808 | -3,954 | -10,503 | -18,892 | -1,099 |
| Investing Cash Flow | $73,722 | $-388,834 | $-435,661 | $-18,892 | $-1,099 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | 334,774 | N/A | N/A | N/A |
| Common Stock Issued | 517,505 | 251,315 | 392,707 | N/A | N/A |
| Other Financing Activity | 31,111 | 37,102 | 30,895 | 440,835 | 60,058 |
| Financing Cash Flow | $548,616 | $623,191 | $423,602 | $440,835 | $60,058 |
| Beginning Cash Position | 138,388 | 197,218 | 387,823 | 83,682 | 95,443 |
| End Cash Position | 418,425 | 138,388 | 197,218 | 387,823 | 83,682 |
| Net Cash Flow | $280,037 | $-58,830 | $-190,605 | $304,141 | $-11,761 |
| Free Cash Flow | |||||
| Operating Cash Flow | -342,301 | -293,187 | -178,546 | -117,802 | -70,720 |
| Capital Expenditure | -3,808 | -3,954 | -10,503 | -18,892 | -1,099 |
| Free Cash Flow | -346,109 | -297,141 | -189,049 | -136,694 | -71,819 |